CM002

CM002 is a small molecule circadian clock activator being investigated for the treatment of muscular dystrophies, specifically Duchenne muscular dystrophy (DMD). Identified through a clock modulator screen and subsequent optimization, CM002 functions by augmenting the activity of the circadian clock, which in turn exerts transcriptional control over key structural and regenerative pathways in muscle tissue. Mechanistically, it induces the expression of integral components of the dystrophin glycoprotein complex (DGC), including utrophin, alpha-sarcoglycan, and dystrobrevin, and increases levels of integrin beta-1 to reinforce the linkage between the sarcolemma and the extracellular matrix. Preclinical studies in *mdx* mice and human DMD myoblasts have demonstrated that CM002 can restore sarcolemma stability, promote regenerative myogenesis, and significantly improve muscle function and exercise capacity.